Skip to content

Elisabet Manasanch, M.D.

NPI 1053518134ActiveIndividual· Internal Medicine, Medical Oncology· Houston, TX

Internal Medicine, Medical Oncology (M.D.) in Houston, Texas, licensed in TX, with an NPI issued in July 2007. Part D covered 32 prescriptions written in 2024, 88% of them generic. Adaptive Biotechnologies Corporation reported $2,400 in payments in 2025, mostly consulting fees.

Overview

NPI1053518134
StatusActive
Entity typeIndividual
CredentialM.D.
Sole proprietorNo
NPI issuedJul 2, 2007
Last updated in NPPESMay 28, 2014

Specialties and licenses

TaxonomyCodeLicenseState
Internal Medicine, Medical Oncology Primary207RX0202XP8502TX

About license numbers in NPPES

Exclusion screening

ListResultDetails
HHS-OIG LEIE · Nov 10, 2026No matchChecked by NPI and by name + state
North Carolina Medicaid · Nov 11, 2026No match—
New York OMIG · Nov 11, 2026No match—
Ohio Medicaid · Nov 11, 2026No match—
Pennsylvania Medicheck · Nov 11, 2026No match—
Washington HCA · Nov 11, 2026No match—

Official OIG search · How matching works ·Bulk check a roster

Medicare

Enrollment (PECOS)Not in the public enrollment file of Oct 1, 2026

Part D prescriptions in 2024

Prescriptions (claims)32 · 57 30-day fills
Total drug cost$2,076
Generic share88% of claims

Medicare sources and data years

Industry payments (Open Payments)

  • 2025$2,400 · 1 payment from 1 company

Top paying companies in 2025

CompanyAmountPayments
Adaptive Biotechnologies Corporation$2,4001

What the 2025 payments were for

  • Consulting Fee$2,400 · 1 payment

Receiving payments does not imply wrongdoing. What Open Payments covers ·original records

Other medical oncologists in Houston

All 233 medical oncologists in Houston · All medical oncologists in Texas